Actuate Therapeutics (ACTU) vs BioCardia (BCDA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
BioCardia (BCDA) has outperformed Actuate Therapeutics (ACTU) over the past year, losing 25.4% versus a loss of 90.3%. Actuate Therapeutics is the larger company by market cap ($16.3 million vs $16.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACTU | BCDA |
|---|---|---|
| Share price | $0.679 | $1.06 |
| Market cap | $16.31M | $16.05M |
| 1-day change | -6.24% | -2.75% |
| YTD return | -88.91% | -15.20% |
| 1-year return | -90.31% | -25.35% |
| 5-year return | — | -97.59% |
| EPS (TTM) | $-0.87 | $-0.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.49 | $1.80 |
| 52-week low | $0.604 | $0.75 |
| Distance from 52-week high | -92.00% | -41.11% |
| Analyst consensus | none | none |
| Avg. price target upside | +1620.18% | +1362.26% |
| Average volume | 386.51K | 282.05K |
| Shares outstanding | 24.01M | 15.14M |
| Employees | 12 | 17 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BCDA has outperformed ACTU by 65.0 percentage points over the past year.
About Actuate Therapeutics
ACTU stock →Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma.
Healthcare · Biotechnology · 12 employees
About BioCardia
BCDA stock →BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.
Healthcare · Biotechnology · 17 employees
ACTU vs BCDA FAQ
Which is bigger, Actuate Therapeutics or BioCardia?
Actuate Therapeutics (ACTU) is larger, with a market capitalization of $16.31M compared with $16.05M for BioCardia (BCDA).
Which stock has performed better over the past year, ACTU or BCDA?
BCDA returned -25.35% over the past 12 months, compared with -90.31% for ACTU (price return, excluding dividends). Past performance does not predict future results.
Are Actuate Therapeutics and BioCardia in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.